Vaccine and Infectious Disease Organization- International Vaccine Centre (VIDO-InterVac), University of Saskatchewan, Saskatoon, SK, Canada.
Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, AB, Canada.
Am J Reprod Immunol. 2017 Nov;78(5). doi: 10.1111/aji.12732. Epub 2017 Aug 3.
Mucosal vaccines have long been sought after to improve protection though the production of both a mucosal and systemic immune response, and are thought to be particularly effective at the site of induction. Development of such vaccines has, however, been delayed by the general propensity to develop immune tolerance to antigens encountered at mucosal sites. This study aimed to determine whether an appropriately formulated subunit vaccine delivered to the uterine lumen would effectively trigger induction of immunity over tolerance.
Ovalbumin (OVA), truncated glycoprotein D (tGD) from bovine herpesvirus, and a fusion protein of porcine parvovirus VP2 and bacterial thioredoxin (rVP2-TrX) were each formulated with a tri-adjuvant combination of Poly(I : C) (PIC), a host defense peptide (HDP), and a polyphosphazene (PCEP). A single dose of vaccine was delivered either intramuscularly (IM) or into the uterine lumen of intact female rabbits, and the humoral response subsequently evaluated both systemically and at local and distal mucosal sites.
Vaccination through either route-induced antigen-specific humoral responses systemically and within the local (uterus) and distal mucosa (lungs and vagina). The observed mucosal response was not compartmentalized to, or within, the upper genital tract and the degree of response appeared to be at least in part antigen dependant.
The results of this study provide proof of principle that the uterus can be used as an induction site for subunit vaccination and that vaccine formulation with appropriate adjuvants can trigger both systemic and mucosal immunity when administered IM or into the uterine lumen.
黏膜疫苗长期以来一直被人们所追求,以改善通过黏膜和系统免疫反应的保护效果,并且被认为在诱导部位特别有效。然而,由于普遍存在对黏膜部位遇到的抗原产生免疫耐受的倾向,此类疫苗的开发一直受到阻碍。本研究旨在确定将适当配制的亚单位疫苗递送到子宫腔中是否能有效地引发免疫反应而不是免疫耐受。
卵清蛋白(OVA)、牛疱疹病毒的截断糖蛋白 D(tGD)和猪细小病毒 VP2 与细菌硫氧还蛋白(rVP2-TrX)的融合蛋白分别与聚(I:C)(PIC)、宿主防御肽(HDP)和聚膦嗪(PCEP)的三佐剂组合进行配制。单剂量疫苗通过肌内(IM)或子宫腔递送至完整雌性兔体内,随后评估全身性和局部(子宫)和远端黏膜(肺和阴道)的体液反应。
通过任何途径接种疫苗均可在全身和局部(子宫)和远端黏膜(肺和阴道)中诱导抗原特异性体液反应。观察到的黏膜反应没有局限于或局限于上生殖道,并且反应程度似乎至少部分取决于抗原。
本研究的结果提供了一个原理证明,即子宫可作为亚单位疫苗的诱导部位,并且当通过肌内或子宫腔给药时,适当佐剂配制的疫苗可引发全身和黏膜免疫。